<DOC>
	<DOCNO>NCT00006355</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness pyrazoloacridine follow radiation therapy treat adult newly diagnose supratentorial glioblastoma multiforme .</brief_summary>
	<brief_title>Pyrazoloacridine Followed Radiation Therapy Treating Adults With Newly Diagnosed Supratentorial Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose , toxicity , pharmacokinetics pyrazoloacridine adult newly diagnose , supratentorial glioblastoma multiforme treat pyrazoloacridine follow radiotherapy . - Determine response rate , duration disease free survival , survival patient treat regimen . OUTLINE : This dose-escalation , multicenter study . Patients stratify accord type anticonvulsant ( hepatic metabolic enzyme inducer vs hepatic metabolic enzyme moderate inducer noninducers ) . Patients receive pyrazoloacridine ( PZA ) IV 3 hour day 1 . Treatment repeat every 3 week maximum 4 course absence disease progression unacceptable toxicity . Following completion PZA treatment , patient undergo cranial irradiation 5 day week 6 week . Cohorts 3 patient receive escalate dos PZA maximum tolerate dose ( MTD ) determine . Additional patient receive PZA MTD . Patients follow monthly survival . PROJECTED ACCRUAL : A minimum 3 patient accrued phase I total 18-35 patient accrue phase II study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>NSC 366140</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven , newly diagnose , supratentorial , grade IV astrocytoma ( glioblastoma multiforme ) Incompletely resected disease Must measurable contrast enhance tumor postoperative MRI/CT scan PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL Transaminases great 4 time upper limit normal Renal : Creatinine great 1.7 mg/dL Other : No serious concurrent infection medical illness would preclude study therapy No active malignancy within past 5 year except curatively treat carcinoma situ cervix basal cell skin cancer No psychosis require ongoing therapy antipsychotic medication Mini mental score least 15 Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior immunotherapy biologic agent ( include immunotoxins , immunoconjugates , antisense compound , peptide receptor antagonist , interferon , interleukin , tumor infiltrating lymphocyte , lymphokine activate killer cell , gene therapy ) glioblastoma multiforme No concurrent prophylactic growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy : No prior chemotherapy glioblastoma multiforme Endocrine therapy : No prior hormonal therapy glioblastoma multiforme Prior glucocorticoid allow Concurrent corticosteroid allow stable dose ( increase within past 5 day ) Radiotherapy : No prior radiotherapy glioblastoma multiforme Surgery : See Disease Characteristics Recovered immediate postoperative period Other : Greater 10 day since prior anticonvulsant induce hepatic metabolic enzyme ( e.g. , phenytoin , carbamazepine , phenobarbital , primidone , felbamate ) No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>